SCHEMBL3453876

SCHEMBL3453876

CC(C)c1ccc(-c2csc(C(NCCC(=O)NS(C)(=O)=O)c3cccs3)n2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.35
MRE11 P49959 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
MAPT P10636 3/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
GCGR P47871 1/20 0.34
GIPR P48546 1/20 0.34
LMNA P02545 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451983 0.90 MAPT (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3453390 0.88 KDM1A (0.40) GCGRGIPRLMNAMEN1KMT2A
SCHEMBL3453701 0.87 LMNA (0.39) MAPTLMNAMEN1KMT2AADRB3
SCHEMBL5161880 0.77 RAB9A (0.42) MRE11HDAC3HDAC1HDAC2HDAC8
SCHEMBL3452789 0.76 DHODH (0.40) TRPA1MRE11MAPTLMNAMEN1
SCHEMBL3452514 0.76 RAB9A (0.40) TRPA1MRE11HDAC3HDAC1HDAC2
SCHEMBL3451928 0.76 TRPA1 (0.38) TRPA1MRE11MAPTMEN1KMT2A
SCHEMBL5163151 0.75 MEP1B (0.41) TRPA1MRE11HDAC3HDAC1HDAC2
SCHEMBL3451446 0.74 PTPRB (0.39) TRPA1MRE11HDAC3HDAC4HDAC1
SCHEMBL3452543 0.74 MRE11 (0.36) TRPA1MRE11HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R TRPA1 2313/4885MRE11 4849/4885HDAC3 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.